GlassScriptPhysician profile
Charles J Crane
NPI 1710961917
$76,040.09
in general payments reported to CMS, 2019-2025
29 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,633 · 2020: $1,435 · 2021: $693 · 2022: $28K · 2023: $1,286 · 2024: $20K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Food and Beverage: $6,475 · Travel and Lodging: $536 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,057.32 |
| Food and Beverage | $6,474.91 |
| Travel and Lodging | $536.08 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $63,995.62 | 2019-2025 | Travoprost Intraocular Implant - Idose, Idose, Idosetr |
| Biotissue Holdings INC. | $3,457.19 | 2019-2025 | |
| Allergan, INC. | $1,749.23 | 2019-2022 | |
| Abbvie INC. | $1,387.15 | 2022-2025 | Lumigan, Alphagan P, Durysta |
| Alcon Vision LLC | $943.66 | 2019-2025 | Rocklatan, Rhopressa, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $892.61 | 2019-2024 | Tecnis Iol, Tecnis Iol, Veritas Vision System |
| Bausch & Lomb Americas INC. | $753.27 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Sight Sciences, INC. | $661.01 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $279.83 | 2019-2021 | |
| Dompe US, INC. | $276.13 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $204.05 | 2019-2025 | |
| New World Medical,INC. | $172.84 | 2022-2025 | Clearpath, Via360, Streamline |
| Novartis Pharmaceuticals Corporation | $149.99 | 2019-2023 | |
| Rxsight INC | $147.53 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Tarsus Pharmaceuticals, INC. | $147.30 | 2024-2025 | Xdemvy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $144.22 | 2022-2025 | Tyrvaya, Ryzumvi |
| Merz North America, INC. | $109.61 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $74.06 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $72.05 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $64.03 | 2019-2022 | |
| Genentech USA, INC. | $60.97 | 2022 | |
| Horizon Therapeutics Plc | $59.60 | 2022-2023 | Tepezza |
| Amgen INC. | $56.88 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $56.55 | 2024 | Vevye |
| Ocular Therapeutix, INC. | $30.07 | 2020-2024 | Dextenza |
| Shire North American Group INC | $29.42 | 2019 | |
| Merz Pharmaceuticals, LLC | $25.48 | 2021 | |
| Thea Pharma INC. | $24.62 | 2022 | |
| Rayner Intraocular Lenses Limited | $15.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Crane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.